Umbelliprenin from Ferula szowitsiana inhibits the growth of human M4Beu metastatic pigmented malignant melanoma cells through cell-cycle arrest in G1 and induction of caspase-dependent apoptosis

被引:94
作者
Barthomeuf, Chantal [1 ]
Lim, Suzanne [1 ]
Iranshahi, Mehrdad [2 ]
Chollet, Philippe [3 ]
机构
[1] Univ Clermont 1, Lab Pharmacognoise Biotechnol, INSERM, U484,Grp Rech Clin,UFR Pharm, F-63001 Clermont Ferrand, France
[2] Mashhad Univ Med Sci, Fac Pharm, Dept Pharmacognosy & Biotechnol, Mashhad, Iran
[3] INSERM, Ctr Jean Perrin, Grp Rech Clin, U484, Clermont Ferrand, France
关键词
cancer; coumarin; Ferula szowitsiana umbelliprenin; malignant melanoma; cell proliferation; cell-cycle blockade; apoptosis;
D O I
10.1016/j.phymed.2007.04.001
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Metastatic malignant melanoma have a bad prognosis (median survival: 6-8 months) mainly due to the development of lung, hepatic and brain metastases. In this study we have used the resazurin reduction test and FACS analysis to assess the cytostatic and cytotoxic effect of umbelliprenin from Ferula szowitsiana (Apiaceae) on human solid cancer cells and human primary fibroblasts. We have observed that the cell susceptibility to umbelliprenin decreases in the order M4Beu (metastatic pigmented malignant melanoma)> A549 (nonsmall cell lung carcinoma) approximate to PC3 (androgen-resistant prostate carcinoma)> PA1 (ovary teratocarcinoma) >human primary fibroblasts approximate to MCF7 (breast adenocarcinoma)> DLD1 (colon adenocarcinoma). M4Beu cell-proliferation is inhibited through cell-cycle arrest in G I and induction of caspase-dependent apoptosis. The finding that the cytotoxic effect of umbelliprenin is markedly more pronounced in M4Beu cells than in primary fibroblasts, suggests a therapeutic margin. As M4Beu cell proliferation is more potently inhibited by umbelliprenin (IC50 12.3 mu M) than by the citrus coumarin auraptene (7-geranyloxy-coumarin, IC50 17.1 mu M) previously reported capable of inhibiting the prevalence of lung metastasis in mice bearing B16BL6 murine melanoma, our data suggest that umbelliprenin orally administered and foods and folk medicines containing this coumarin, may afford protection against the development and early recurrence of malignant melanoma. In vivo investigations are needed to test these hypotheses. (C) 2007 Elsevier GmbH. All rights reserved.
引用
收藏
页码:103 / 111
页数:9
相关论文
共 31 条
[1]   Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours [J].
Bajetta, E ;
Ferrari, L ;
Procopio, G ;
Catena, L ;
Ferrario, E ;
Martinetti, A ;
Di Bartolomeo, M ;
Buzzoni, R ;
Celio, L ;
Vitali, M ;
Beretta, E ;
Seregni, E ;
Bombardieri, E .
ANNALS OF ONCOLOGY, 2002, 13 (04) :614-621
[2]   In vitro activity of hederacolchisid A1 compared with other saponins from Hedera colchica against proliferation of human carcinoma and melanoma cells [J].
Barthomeuf, C ;
Debiton, E ;
Mshvildadze, V ;
Kemertelidze, E ;
Balansard, G .
PLANTA MEDICA, 2002, 68 (08) :672-675
[3]   COMBINATION CHEMOTHERAPY OF METASTATIC MELANOMA [J].
BERD, D ;
MASTRANGELO, MJ .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (03) :796-796
[4]   ORGANIC CONSTITUENTS OF FOOD .2. CELERY [J].
CROSBY, DG ;
ANDERSON, LJ .
JOURNAL OF FOOD SCIENCE, 1963, 28 (06) :640-&
[5]  
Curini Massimo, 2006, Anti-Cancer Agents in Medicinal Chemistry, V6, P571, DOI 10.2174/187152006778699149
[6]   In addition to membrane injury, an affinity for melanin might be involved in the high sensitivity of human melanoma cells to hederacolchiside A1 [J].
Debiton, E ;
Borel, M ;
Communal, Y ;
Mshvildadze, V ;
Barthomeuf, C .
MELANOMA RESEARCH, 2004, 14 (02) :97-105
[7]  
DELEAN A, 1998, USERS GUIDE ALLFIT
[8]   Long-term disease-free survival in advanced melanomas treated with nitrosoureas: mechanisms and new perspectives [J].
Durando, X ;
Thivat, E ;
D'Incan, M ;
Sinsard, A ;
Madelmont, JC ;
Chollet, P .
BMC CANCER, 2005, 5 (1)
[9]  
DWARDS DJ, 1999, CLIN PHARMACOL THER, V65, P237
[10]   Cancer statistics, 2001 [J].
Greenlee, RT ;
Hill-Harmon, MB ;
Murray, T ;
Thun, M .
CA-A CANCER JOURNAL FOR CLINICIANS, 2001, 51 (01) :15-36